Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

NCT02956382 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT02956382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02956382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Lead sponsor
Georgetown University
Phase
Phase 1/2
Overall status
Completed
Start date
March 1, 2017
Completion date
March 7, 2024
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

refractory follicular lymphoma, relapsed follicular lymphoma